Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Sanofi”

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and OlderCompleted
NCT05553301Phase 1, Phase 2Updated Jan 24, 2025
Sponsor: Sanofi Pasteur, a Sanofi Company
Influenza Immunization
United States, Puerto Rico
An Observational Study on Sarilumab-exposed PregnanciesCompleted
NCT03378219N/AUpdated Jan 17, 2025
Sponsor: Sanofi
Rheumatoid Arthritis -Exposure During Pregnancy
United States, Canada
Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsCompleted
NCT02990338Phase 3Updated Jan 17, 2025
Sponsor: Sanofi
Plasma Cell Myeloma
United States, Australia, Belgium, Canada, Czechia +19 more
Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompleted
NCT05283915Phase 1Updated Jan 15, 2025
Sponsor: Sanofi
Hepatic Function Abnormal
United States
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any StageCompleted
NCT03025789Phase 3Updated Jan 8, 2025
Sponsor: Drugs for Neglected Diseases
Trypanosomiasis, African · Sleeping Sickness · Trypanosomiasis; Gambian
Democratic Republic of the Congo, Guinea
A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as Capsules to Healthy Adult Male Participants (Part B)Completed
NCT05797753Phase 1Updated Jan 3, 2025
Sponsor: Sanofi
Amyotrophic Lateral Sclerosis · Healthy Volunteer
United States
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC PatientsCompleted
NCT00418886Phase 3Updated Dec 31, 2024
Sponsor: Genzyme, a Sanofi Company
Non Small Cell Lung Cancer · Lung Cancer
United States, Argentina, Australia, Belgium, Colombia +16 more
Sweetheart-Register: Risk Management of Diabetics with Acute Myocardial InfarctionCompleted
NCT01197742N/AUpdated Dec 20, 2024
Sponsor: Stiftung Institut fuer Herzinfarktforschung
Diabetes · STEMI · NSTEMI · Myocardial Infarction
Germany
Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)Completed
NCT06469359NAUpdated Dec 18, 2024
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Healthy Volunteers
France
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid CancerCompleted
NCT01945762N/AUpdated Dec 18, 2024
Sponsor: Genzyme, a Sanofi Company
Symptomatic, Aggressive, Sporadic, Unresectable, Locally · Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Belgium, France, Germany, Italy, Luxembourg +3 more
Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 DiabetesCompleted
NCT02049034Phase 4Updated Dec 16, 2024
Sponsor: University of Surrey
Type 2 Diabetes
United Kingdom
Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)Recruiting
NCT05017142N/AUpdated Dec 16, 2024
Sponsor: University of Bern
Optic Neuritis · Transverse Myelitis · Acute Disseminated Encephalomyelitis · Multiple Sclerosis
Switzerland
Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic TherapyTerminated
NCT03640481Phase 2Updated Dec 12, 2024
Sponsor: Kadmon, a Sanofi Company
Chronic Graft-versus-host-disease
United States
Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with IsatuximabRecruiting
NCT05053607NAUpdated Dec 11, 2024
Sponsor: Pack Health
Multiple Myeloma · Refractory Multiple Myeloma
United States
Factors Influencing the COVID-19 Vaccine Immune Response According to Age and Presence or Not of a Past History of COVID-19Completed
NCT05047718Phase 4Updated Dec 11, 2024
Sponsor: Centre Hospitalier Universitaire de Saint Etienne
Covid19
France
Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate CancerCompleted
NCT02218606Phase 2Updated Dec 10, 2024
Sponsor: Memorial Sloan Kettering Cancer Center
Prostate Cancer
United States
A Phase 4, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent AsthmaCompleted
NCT04502862Phase 4Updated Dec 6, 2024
Sponsor: Sanofi
Asthma
United States, Argentina, Canada, Germany, Italy +6 more
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)Terminated
NCT04661033Phase 2Updated Dec 5, 2024
Sponsor: Sanofi
Warm Autoimmune Hemolytic Anemia (wAIHA)
United States, France, Germany, Italy, Netherlands +1 more
Safety of Fresolimumab in the Treatment of Osteogenesis ImperfectaCompleted
NCT03064074Phase 1Updated Dec 4, 2024
Sponsor: Baylor College of Medicine
Osteogenesis Imperfecta
United States
Carac & PDT Combination in the Treatment Of Actinic KeratosesCompleted
NCT06712381Phase 1, Phase 2Updated Dec 2, 2024
Sponsor: Skin Laser & Surgery Specialists
Actinic Keratoses
Deep sequencIng in Cutaneous Squamous CEll caRciNomasActive Not Recruiting
NCT05878288Phase 2Updated Nov 21, 2024
Sponsor: Peter MacCallum Cancer Centre, Australia
Cutaneous Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Neoplasms · Non-melanoma Skin Cancer
Australia
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)Completed
NCT06698198Phase 1Updated Nov 20, 2024
Sponsor: Sanofi Pasteur, a Sanofi Company
Pneumococcal Immunization
United States
Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)Completed
NCT05908656NAUpdated Nov 19, 2024
Sponsor: Sanofi
Gaucher Disease
United States
Patient with Atopic Dermatitis' Needs for Self-management Support - Flexible Patient Centred ConsultationsActive Not Recruiting
NCT06032403NAUpdated Nov 18, 2024
Sponsor: University Hospital, Gentofte, Copenhagen
Atopic Dermatitis
Denmark
An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe AsthmaCompleted
NCT06064526N/AUpdated Nov 14, 2024
Sponsor: Sanofi
Asthma
France

Previous page Next page